Glycolipid antigen presentation pathway

The glycolipid antigen presentation pathway is a cellular mechanism by which specialized antigen-presenting molecules, particularly the CD1 family (CD1a, CD1b, CD1c, CD1d), bind and present glycolipid antigens to T cells. Unlike peptide antigens, which are presented by classical MHC class I and II molecules, glycolipid antigens are presented by CD1 molecules. This process involves the uptake of glycolipids, processing in endosomal or lysosomal compartments, and loading onto CD1 molecules, which then display the hydrophilic 'head' group of the glycolipid for recognition by T-cell receptors, particularly those on invariant Natural Killer T (iNKT) cells[1][2][3][5][6]. The process is crucial for immune recognition of both self and microbial glycolipids and is implicated in various disease states, including infections (e.g., tuberculosis), autoimmune disorders, and cancer[2][3][5][7]. Therapeutically, drugs do not target the "pathway," but synthetic glycolipids (such as α-GalCer) can modulate immune responses via iNKT cell activation, making specific CD1 isoforms (e.g., CD1d) a therapeutic target[3]. Key clarification: - The "glycolipid antigen presentation pathway" is a functional *process* not a druggable molecular target or discrete receptor/enzyme. The most relevant targets within this pathway are the **CD1 molecules** (notably CD1d), and the *pathway* as such should not be listed as a canonical biomolecular target. - For structured information on a therapeutic target, use "CD1d molecule" or specific CD1 isoforms, not the general pathway.

Other names

Lipid antigen presentationCD1-mediated antigen presentationCD1 pathway

Not applicable for pathway; see CD1d for drug mechanisms